海角直播

National Horizons Centre announced as a preferred bidder as a National Training Centre

海角直播鈥檚 National Horizons Centre (NHC) has been identified as a preferred bidder as a National Training Centre to deliver cutting-edge training in cell and gene therapy and vaccine manufacturing.

The selection of the NHC as a National Training Centre for the Advanced Therapies Skills Training Network (ATSTN) further cements the Tees Valley鈥檚 growing reputation as a global hub for the bioscience sector. Alongside RoslinCT in Edinburgh and the University of Birmingham, the NHC is one of three preferred bidders for National Training Centres which will deliver high impact physical and digitally-delivered training courses as part of the growing ATSTN programme.

The NHC, which is based at 海角直播鈥檚 Darlington campus at Central Park, opened in 2019 to deliver research, education and collaboration to help grow the UK鈥檚 bioscience sector.

ATSTN is a nationwide skills development programme driven by industry and coordinated by the Cell and Gene Therapy Catapult, funded by 拢4.7m as part of the Government鈥檚 commitment to expand the UK鈥檚 expertise in advanced therapies and vaccine manufacturing.

A core aim of the ATSTN is to develop a coordinated network of National Training Centres to deliver specialist on-site courses, including innovative digital training utilising virtual reality, providing learners with the hands-on expertise and experience to succeed in the advanced therapies and vaccine manufacturing sector.

Dr Jen Vanderhoven, Director of the National Horizons Centre, said: 鈥淐ollaboration is the key to success, and I am delighted that the NHC has been chosen as one of the national ATSTN centres to provide the vital training of the future advanced therapies and vaccines workforce.

鈥淭he NHC, with its leading expertise and state of the art bioprocessing and virtual reality capabilities, is perfectly positioned to up-skill and cross-skill hundreds of people in the coming months.

鈥淲e will deliver the necessary technical hands-on training to create the workforce needed to manufacture vaccines and advanced therapies, to overcome COVID-19 and any future pandemics and diseases.

鈥淲e look forward to collaboratively working with the other centres and the Cell and Gene Therapy Catapult, to create a truly world-class offering that puts the UK at the forefront of ATMP (advanced therapy medicinal products) and vaccine manufacturing.鈥�

Matthew Durdy, Chief Executive Officer at Cell and Gene Therapy Catapult, said: 鈥淲e are looking forward to collaborating with the National Horizons Centre which will bring its expertise, industry-leading bioprocessing and virtual reality capabilities to this programme.

鈥淭his is a significant step in driving the effective development and rollout of state-of-the-art and impactful training courses which can rapidly upskill and attract talent within the advanced therapies and vaccine manufacturing industry.

鈥淭he involvement of the National Horizons Centre will enable the ATSTN to provide users with a wide variety of exciting training resources which are at the forefront of innovation. I look forward to witnessing the impact which the NHC will make as part of this valued collaboration over the years to come.鈥�